Powering EGFR mutation research in NSCLC
Cancer research

Powering EGFR mutation research in NSCLC

Global Solid Tumor Summit

Global Solid Tumor Summit

On April 25 and 26, hear how advances in technology, such as dPCR and NGS are driving improvements in biomarker testing in solid tumors.

The world’s deadliest cancer

Did you know that lung cancer is the leading cause of cancer mortality, worldwide (1)? In the US, it’s the second most common cancer and the leading cause of cancer mortality, with over 228,000 new cases and 138,000 deaths in 2020 (1). Non-small cell lung cancer (NSCLC) makes up about 85% of those cases (2).

QIAseq Targeted Methyl Panels

The role of EGFR in NSCLC

Although many oncogenes are involved in NSCLC, mutations in the EGFR gene occur in ~15% of NSCLC adenocarcinomas – that’s 1 in every 7 cases. Research into the role of EGFR mutations is therefore vitally important in the fight against this type of cancer.

Next-day results for streamlined research

Our EGFR Plus RGQ PCR Kit is a real-time PCR assay that provides next-day results. A choice of automated or manual sample prep, followed by a simple, ready-to-use system enables you to take your research further - faster. Work with FFPE tissue or plasma samples. For maximum flexibility, you can run both sample types within the same PCR run.

Woman in lab smiling


  1. GLOBOCAN 2020. http://gco.iarc.fr/today. Accessed: July 28, 2022.